Successful treatment of SAPHO syndrome with oral abrocitinib: a case report
Aim SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint inflammation). This study aims to evaluate the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2437259 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115072433586176 |
|---|---|
| author | Zhipeng Lin Songyi Piao Rongxin Zhang Chao Yu Zhao Hou Aoxue Wang |
| author_facet | Zhipeng Lin Songyi Piao Rongxin Zhang Chao Yu Zhao Hou Aoxue Wang |
| author_sort | Zhipeng Lin |
| collection | DOAJ |
| description | Aim SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint inflammation). This study aims to evaluate the therapeutic efficacy and safety of Janus kinase 1 (JAK1) inhibitor abrocitinib in patients with SAPHO syndrome.Methods We presented a patient with SAPHO syndrome with accelerated disease progression who did not respond to traditional therapies. The patient was treated with oral abrocitinib at a dosage of 100 mg daily.Results After 3 months of treatment with abrocitinib, the patient exhibited considerable symptom improvement with no new facial lesions. The joint pain was completely relieved after abrocitinib administration for 15 months. No adverse events or recurrences were reported during the 18-month follow-up period.Conclusions Abrocitinib monotherapy may be a promising treatment option for patients with SAPHO syndrome. |
| format | Article |
| id | doaj-art-737f3cc4cec140728f9c88e701a45e49 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-737f3cc4cec140728f9c88e701a45e492025-08-20T02:36:40ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2437259Successful treatment of SAPHO syndrome with oral abrocitinib: a case reportZhipeng Lin0Songyi Piao1Rongxin Zhang2Chao Yu3Zhao Hou4Aoxue Wang5Department of Dermatology, The Second Hospital of Dalian Medical University, Dalian, ChinaDepartment of Dermatology, The Second Hospital of Dalian Medical University, Dalian, ChinaDepartment of Dermatology, The Second Hospital of Dalian Medical University, Dalian, ChinaDepartment of Dermatology, The Second Hospital of Dalian Medical University, Dalian, ChinaDepartment of Dermatology, The Second Hospital of Dalian Medical University, Dalian, ChinaDepartment of Dermatology, The Second Hospital of Dalian Medical University, Dalian, ChinaAim SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint inflammation). This study aims to evaluate the therapeutic efficacy and safety of Janus kinase 1 (JAK1) inhibitor abrocitinib in patients with SAPHO syndrome.Methods We presented a patient with SAPHO syndrome with accelerated disease progression who did not respond to traditional therapies. The patient was treated with oral abrocitinib at a dosage of 100 mg daily.Results After 3 months of treatment with abrocitinib, the patient exhibited considerable symptom improvement with no new facial lesions. The joint pain was completely relieved after abrocitinib administration for 15 months. No adverse events or recurrences were reported during the 18-month follow-up period.Conclusions Abrocitinib monotherapy may be a promising treatment option for patients with SAPHO syndrome.https://www.tandfonline.com/doi/10.1080/09546634.2024.2437259AbrocitinibJAK1SAPHO syndrometreatment |
| spellingShingle | Zhipeng Lin Songyi Piao Rongxin Zhang Chao Yu Zhao Hou Aoxue Wang Successful treatment of SAPHO syndrome with oral abrocitinib: a case report Journal of Dermatological Treatment Abrocitinib JAK1 SAPHO syndrome treatment |
| title | Successful treatment of SAPHO syndrome with oral abrocitinib: a case report |
| title_full | Successful treatment of SAPHO syndrome with oral abrocitinib: a case report |
| title_fullStr | Successful treatment of SAPHO syndrome with oral abrocitinib: a case report |
| title_full_unstemmed | Successful treatment of SAPHO syndrome with oral abrocitinib: a case report |
| title_short | Successful treatment of SAPHO syndrome with oral abrocitinib: a case report |
| title_sort | successful treatment of sapho syndrome with oral abrocitinib a case report |
| topic | Abrocitinib JAK1 SAPHO syndrome treatment |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2437259 |
| work_keys_str_mv | AT zhipenglin successfultreatmentofsaphosyndromewithoralabrocitinibacasereport AT songyipiao successfultreatmentofsaphosyndromewithoralabrocitinibacasereport AT rongxinzhang successfultreatmentofsaphosyndromewithoralabrocitinibacasereport AT chaoyu successfultreatmentofsaphosyndromewithoralabrocitinibacasereport AT zhaohou successfultreatmentofsaphosyndromewithoralabrocitinibacasereport AT aoxuewang successfultreatmentofsaphosyndromewithoralabrocitinibacasereport |